chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Placed in fridge Nov. 15Administered today; No adverse event; This spontaneous case was reported by an other health care professional and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (Placed in fridge Nov. 15Administered today) and NO ADVERSE EVENT (No adverse event) in an adult patient of an unknown gender who received mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (batch no. AS7167B) for COVID-19 prophylaxis.     No Medical History information was reported.    On 23-Dec-2022, the patient received dose of mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (unknown route) 1 dosage form. On 23-Dec-2022, the patient experienced EXPIRED PRODUCT ADMINISTERED (Placed in fridge Nov. 15Administered today) and NO ADVERSE EVENT (No adverse event). At the time of the report, EXPIRED PRODUCT ADMINISTERED (Placed in fridge Nov. 15Administered today) and NO ADVERSE EVENT (No adverse event) outcome was unknown.        For mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (Unknown), the reporter considered NO ADVERSE EVENT (No adverse event) to be not related. No further causality assessment was provided for EXPIRED PRODUCT ADMINISTERED (Placed in fridge Nov. 15Administered today).    No concomitant medication information was reported. No treatment medication information was reported.
Intermittant  Numbess and tingling in left arm that started 2-3 weeks after first shot and still persists which is now over 2 months   Saw neurologist due to these symptoms and he is ordering an EMG and is attributing it to my receiving the vaccine.
Information has been received from a nurse concerning a female who on 11-OCT-2007 was vaccinated with ZOSTER (lot # not reported). On 17-OCT-2008, "about 1 year after" vaccination with ZOSTER, the patient experienced shingles. The patient sought medical attention. No further information is available.
pt exp soreness & tenderness @ the inj site & erythema 31MAY95;pt recvd vax 30MAY95;
Information was received from a physican concerning a patient who was vaccinated "in another country" with a dose of Varicella virus vaccine live.  Subsequently the patient developed chickpox lesions all over the body.  Unspecified medical attention was sought.  There was no product quality complaint.  Additional information was requested.
He died , found dead after 24 hours, Closed casket, no foul play.   I  am unable to get an autopsy.
diagnosed with Covid and he is on the morning dose of day 4 of Paxlovid; diagnosed with Covid and he is on the morning dose of day 4 of Paxlovid; This is a spontaneous report received from contactable reporter(s) (Consumer or other non HCP) from medical information team and product quality group. The reporter is the patient.  A 63-year-old male patient received BNT162b2 (BNT162B2), on 31Mar2021 as dose 1, single (Lot number: EP7533), in left arm, on 24Apr2021 as dose 2, single (Lot number: EW0164), in left arm and on 05Jan2022 as dose 3 (booster), single (Lot number: 331308A) at the age of 62 years, in left arm for covid-19 immunisation; influenza vaccine (FLU), on 05Jan2022 as dose number unknown, single (Batch/Lot number: unknown) for influenza immunisation. The patient's relevant medical history included: "cancer" (unspecified if ongoing), notes: Prior to vaccines and states he is now 8 years cancer free. The patient's concomitant medications were not reported. The following information was reported: VACCINATION FAILURE (medically significant), COVID-19 (medically significant) all with onset 25Apr2022, outcome "recovering" and all described as "diagnosed with Covid and he is on the morning dose of day 4 of Paxlovid". The events "diagnosed with covid and he is on the morning dose of day 4 of paxlovid" required physician office visit. The patient underwent the following laboratory tests and procedures: SARS-CoV-2 test: (25Apr2022) Positive. Therapeutic measures were taken as a result of vaccination failure, covid-19.  Clinical course: Can I get my fourth booster dose or do I need to wait" Caller states all three doses of the Covid 19 vaccine he has received are Pfizer.  He has a compromised immune system and he had cancer. Agent states the caller is a consumer who states he has been vaccinated with both Pfizer vaccines, and boosted, and was just diagnosed with Covid and is on the morning dose of Paxlovid, Day 4. Agent states the caller's question was, after he completed the Paxlovid should he get his booster dose or should he wait-agent states she was unable to answer his question because they did not study this in the trials. Patient did not require a visit to Emergency Room.
He got his vaccines and had no reaction at all for 10 days.  Then all of a sudden around the injection site about 2-3" around the injection site had this in the morning, and it started hurting and itching.  He has often had a reaction the day after, but not after 10 days.  He has a friend who is a pharmacist and told him about and he said that it may be a reaction.  He talked to the pharmacist where he got the vaccine, looked at it, did not look infected, probable delayed reaction, and that RSV is new and they don't have a lot of info.  He has an annoying pain in that arm, and every now and then he has itching too.  It has not reduced much in strength or presents.  It is not hot or red looks completely normal, has a very slight bump in that area as well.  in the leaflet it said to take Tylenol and Ibuprofen which he has taken both for the pain usually at night.  He has not contacted his doctor, only the pharmacists.
COVID breakthrough. Patient presented to the emergency department on 11/5/21 with 2 days of generalized weakness/fatigue and diarrhea. She was tested for COVID on 11/9/21.
Initially began with headache and fatigue the first afternoon - which was expected. After a few days the headache and fatigue had subsided, although not all the way, and was replaced by a dry cough. After two weeks now those symptoms have not subsided. I had COVID 11 months before my first Pfizer shot, and the symptoms from the Pfizer shot were exactly the same as COVID-19, so I went and got re-tested. I tested negative for COVID. I have now had a light headache, fatigue, and a sore throat/dry cough for two weeks since the 1st dose of Pfizer. I have missed two days of work while checking to see if this was actually COVID.
Extreme muscle and joint pain. For 2 days. First day after shot I couldn?t get out of bed.  Same feeling as the COVID toes I had with COVID-19  Shot site soreness for 1 week following the vaccine.
Pregnancy; This spontaneous prospective pregnancy case was reported by a consumer and describes the occurrence of MATERNAL EXPOSURE DURING PREGNANCY (Pregnancy) in a 35-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 037K2DA) for COVID-19 vaccination.     Concomitant products included LEVOCETIRIZINE DIHYDROCHLORIDE (XYZAL) and MOMETASONE FUROATE (FLONASE [MOMETASONE FUROATE]) for Allergy, MINERALS NOS, VITAMINS NOS (PRENATAL VITAMINS [MINERALS NOS;VITAMINS NOS]) for an unknown indication.    On 06-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) .5 ml. The patient's last menstrual period was on an unknown date and the estimated date of delivery was 10-Jun-2021. On 06-Jan-2021, the patient experienced MATERNAL EXPOSURE DURING PREGNANCY (Pregnancy). On 06-Jan-2021, MATERNAL EXPOSURE DURING PREGNANCY (Pregnancy) had resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       No treatment related information has been reported.; Sender's Comments: This is a case of vaccine exposure during pregnancy with no associated AEs for this 35 year old female. Patient will continue to be contacted for further monitoring of AEs during the pregnancy
Pt Age 47 female c/o dizziness. Assessed Bp 142/89 Hr 102 Pt reported no hx of htn tachycardia or diabetes. Pt reported no intake of H2O in last 12 hrs. Pt reported hx of anxiety, encouraged H2O offered H2O. Pt drank 95% of water bottled. Advised Pt to wait an extra 15 mins in post Vac observation to which pt denied against medical advice. Pt waked out clinic @ 1537pm expressing "she felt much better".
Frequent urination; This spontaneous case was reported by a consumer and describes the occurrence of POLLAKIURIA (Frequent urination) in a 75-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 028L20A and 014M20A) for COVID-19 vaccination.     The patient's past medical history included Cystitis interstitial.   On 27-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 24-Feb-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On 25-Feb-2021, the patient experienced POLLAKIURIA (Frequent urination). The patient was treated with IBUPROFEN at a dose of UNK dosage form. At the time of the report, POLLAKIURIA (Frequent urination) outcome was unknown.            No concomitant medication was provided. Action taken with mRNA-1273 in response to the event was not applicable.
This spontaneous report received from a healthcare worker refers to a 33 years old patient of unknown gender. On 13-NOV-2014, patient was vaccinated with an improperly stored dose of M-M-R II (lot# J016232, Expiry: 19-DEC-2015, dose number 2) (dose and route was unknown). No adverse effects reported. This is one of the several reports linked with the same reporter link. No further information was available. Additional information has been requested.
Very sore and painful at site of injection; 2-3 days duration Elevated temperature (99.4) for 24 hours Lethargy 24 hours
Itchy and tingly  hands/arms in morning of 2/22/21. Rash broke out on body in the evening (face, legs, shoulders, waist, thighs/groin). Took a Benadryl and ibuprofen. Symptoms improved  by morning, but still evidence of the rash. Took normal allegry meds in AM. Will monitor symptoms moving forward.
Initial misuse report received from a healthcare professional on 27-Aug-2013. The case was received on 21-Mar-2014. This is an invalid case as individual patient identifiers are not reported. The patient had received unstable YF vaccine. This one gave a dose of YF vaccine 2 weeks post MMR. Now she wants to give another dose of YF vaccine much earlier than the 28 days. According to the CDC if the 2 live vaccines are not administered the same day there is a 28 day waiting pd. This is in the CDC yellow book and the gen rec immuniz. Administration of a live-virus vaccine stimulates not only specific immune responses but also non-specific responses, such as increased levels and activity of interferon. This interferon can impair responsiveness to another live virus vaccine if given before the interferon settles down. So, wait at least 28 days between live virus vaccines. If injectable or nasally administered live vaccines are separated by <4 weeks, the second vaccine administered should not be counted as a valid dose and should be repeated. The repeat dose should not be administered greater than or equal to 4 weeks after the last invalid dose. I do not have anything from CDC advocating 4 days earlier. No adverse event was reported. (No information was provided regarding the patients). List of documents held by sender: none.
Initial redness and swelling ~4cm. 24 hours after vaccine. Pain with walking x 3 days. Small hematoma noted 9/22/22 2x10mm.
The pt developed fussiness since receiving vaccinations on 05/20/2002. On 05/29/2002, child developed chicken pox lesions. Seen in clinic on 05/30/2002. Also has BOM.
extremely dizzy, nystagmus, unable to walk straight, course lasted about 3 weeks, did not relate it to vaccine until found out mother had same symptoms
Lost use of legs 12 hours,inability to talk, semi-unconscious,excessive sleepy. Cramping of joints and hands, lethargic.confused,dazed,
Throat itchy, lips felt tight immediately after vaccination.  Only last few minutes and then everything returned to normal.  Patient followed up with provider and denied having any further adverse reactions.
Patient should have received Flucelvax instead of Fluad due to age. No adverse events at this time.
The next day I developed what I thought was a cold but it transitioned into pneumonia and wasn't resolved until April. Mid June, I had an acute hypertensive crisis, I lost my ability to speak and was incoherent, my BP was 214/108, and I had high heart rate went to to meet with doctor. She sent me for CAT Scan at Providence Milwaukie Hospital and they admitted me for a day to hospital due to my high blood pressure. My eyes have gotten terrible and show blood clots and I see an ophthalmologist regularly, I have lost my ability to focus.  Northwest eyecare professionals. 503-657-0321
Headache, Myalgia, Fever, SWELLING, REDNESS Narrative:  Other Relevant History:
Expired Boostrix administered; This case was reported by a nurse via call center representative and described the occurrence of expired vaccine used in a 11-year-old male patient who received DTPa (Reduced antigen) (Boostrix) (batch number XK524, expiry date 8th October 2022) for prophylaxis.   On 12th October 2022, the patient received Boostrix. On 12th October 2022, unknown after receiving Boostrix, the patient experienced expired vaccine used. On an unknown date, the outcome of the expired vaccine used was unknown.   Additional Information: GSK receipt date: 12-Oct-2022 Reporter's comment: The vaccine administration facility was the same as primary reporter. The reporter consented to follow-up. Additional supportive information: The patient received an expired dose of Boostrix, which led to expired vaccine used.
It was reported that a 9 month old female patient received an IPOL vaccination in her right thigh and a Hepatitis B vaccination in her left thigh on 4/16/01. Reportedly the next day the patient developed a 2cmx1cm red swollen area below injection site (site not specified). Patient also developed a low grade fever of 101.5. From mailed correspondence received on 6/29/01 it was reported that the patient recovered from this experience. Additional patient, vaccine administrator and responsible physician information was also provided. This case is closed.
broken blood vessel in the right eye; not getting sleep; Achy; A spontaneous report ) was received from a consumer concerning a 74-years-old female patient who received Moderna's COVID-19 vaccine (mRNA-1273) and was achy, not getting sleep and broken blood vessel in her right eye.   The patient's medical history was not provided. No relevant concomitant medications were reported.  On 02 Mar 2021, prior to the onset of the events, the patient received their first of two planned doses of mRNA-1273 (lot/batch: 036A21A) intramuscularly in the right arm for prophylaxis of COVID-19 infection.  On 2 Mar 2021, the patient was achy and was not getting sleep. On 05 Mar 2021, she had a broken blood vessel in her right eye. She stated that she was better but her right eye was still red. No treatment information was provided.  Action taken with mRNA-1273 in response to the events achy, not getting sleep and broken blood vessel in her right eye was unknown.  The seriousness criterion for the event broken blood vessel in her right eye was medically significant.  The outcome of the event, broken blood vessel in the right eye was not resolved, while the outcome of the events not getting sleep and achy was resolving.; Reporter's Comments: Very limited information regarding this event/s has been provided at this time.  Further information has been requested.
no adverse effects reported; patient was vaccinated with improperly stored MMR II; This spontaneous report has been received from a medical assistant, concerning a patient of unknown age and gender. The patient's medical history, concurrent conditions and concomitant medications were not provided.  On 08-MAY-2019,  the patient was vaccinated with improperly stored dose of measles, mumps, and rubella (wistar ra 27-3) virus vaccine, live(M-M-R II) (albumin status rHA) one dose, lot # R024906 with expiration date 30-AUG-2020 (frequency, route and anatomical location were not provided) which was reconstituted with sterile diluent (dose, frequency, route, lot number and expiration date were not provided) for prophylaxis. No adverse effects reported.  The temperature and time frame were unknown by reporter. There was previously temperature excursions and digital data logger was involved.  This is one of several reports received from the same reporter.; Sender's Comments:  US-009507513-1906USA011469: US-009507513-1907USA010301: US-009507513-1907USA010302: US-009507513-1907USA010303: US-009507513-1907USA010304: US-009507513-1907USA010305: US-009507513-1907USA010306: US-009507513-1907USA010307: US-009507513-1907USA010308: US-009507513-1907USA010309: US-009507513-1907USA010310: US-009507513-1907USA010311: US-009507513-1907USA010312: US-009507513-1907USA010313: US-009507513-1907USA010314: US-009507513-1907USA010315: US-009507513-1907USA010316: US-009507513-1907USA010317: US-009507513-1907USA010318: US-009507513-1907USA010319: US-009507513-1907USA010320: US-009507513-1907USA010321: US-009507513-1907USA010322: US-009507513-1907USA010323: US-009507513-1907USA010324: US-009507513-1907USA010325: US-009507513-1907USA010326: US-009507513-1907USA010327: US-009507513-1907USA010328: US-009507513-1907USA010329: US-009507513-1907USA010330: US-009507513-1907USA010331: US-009507513-1907USA010332: US-009507513-1907USA010333: US-009507513-1907USA010334: US-009507513-1907USA010335: US-009507513-1907USA010336: US-009507513-1907USA010337: US-009507513-1907USA010338: US-009507513-1907USA010339: US-009507513-1907USA010340: US-009507513-1907USA010341: US-009507513-1907USA010342: US-009507513-1907USA010343: US-009507513-1907USA010344: US-009507513-1907USA010345: US-009507513-1907USA010346: US-009507513-1907USA010347: US-009507513-1907USA010348: US-009507513-1907USA010349: US-009507513-1907USA010350: US-009507513-1907USA010351: US-009507513-1907USA010352: US-009507513-1907USA010353: US-009507513-1907USA010354: US-009507513-1907USA010355: US-009507513-1907USA010356: US-009507513-1907USA010357: US-009507513-1907USA010358: US-009507513-1907USA010359: US-009507513-1907USA010360: US-009507513-1907USA010361: US-009507513-1907USA010362: US-009507513-1907USA010363: US-009507513-1907USA010364: US-009507513-1907USA010366: US-009507513-1907USA010367: US-009507513-1907USA010368: US-009507513-1907USA010369: US-009507513-1907USA010370: US-009507513-1907USA010371: US-009507513-1907USA010372: US-009507513-1907USA010373:
Patient presented to emergency room on 9/29/2021 with shortness of breath. Patient was found to be COVID-19 on 9/25/2021 during an emergency department visit and was treated with monoclonal antibodies.  Since infusion, he was experiencing increasing shortness of breath and a fever. He was admitted for further management. Patient was discharged home on 10/1/2021.
10-12 hrs p/inject itching on arms progressed to full body itching; hives eruption started on arms progressed to full body in noc time; sought MD opinion in AM but lacked transportation to appt;
Approx 5  mins after administering Immunx pt dizzy saw white and lost consciousness falling to floor. Under for approx 15 secs Awoke up- VS stable remained sitting x 5 mins then ambulated out of office
EXTENDED FATIGUE; This spontaneous report received from a patient concerned a male of unspecified age. The patient's height, and weight were not reported. The patient's pre-existing medical conditions included the patient took shingles vaccine.The patient received covid-19 vaccine ad26.cov2.s (suspension for injection, route of admin not reported, batch number: Unk) dose, start therapy date were not reported for prophylactic vaccination. The batch number was not reported. The Company is unable to perform follow-up to request batch/lot numbers. No concomitant medications were reported. On an unspecified date, the subject experienced extended fatigue. The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The patient was recovering from extended fatigue. This report was non-serious.
Body aches; fever; Stomach ache; No energy; This spontaneous case was reported by a patient family member or friend and describes the occurrence of ABDOMINAL PAIN UPPER (Stomach ache), ASTHENIA (No energy), PAIN (Body aches) and PYREXIA (fever) in a 62-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On 23-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 24-Mar-2021, the patient experienced ABDOMINAL PAIN UPPER (Stomach ache) and ASTHENIA (No energy). On 25-Mar-2021, the patient experienced PYREXIA (fever). On an unknown date, the patient experienced PAIN (Body aches). At the time of the report, ABDOMINAL PAIN UPPER (Stomach ache), ASTHENIA (No energy), PAIN (Body aches) and PYREXIA (fever) had not resolved. Unknown      The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       Concomitant medications included unspecified blood pressure medication.  Reportedly, the patient was experiencing this for two weeks every day. The patient went to urgent care and they gave her some Tylenol and Motrin. Also, some medicine for her stomach. The patient started having Motrin medicine for fever. The patient still had fever, body aches and no energy.
Left arm was so painful for almost 48 hours after the second dose; I could barely move the arm, making it difficult to dress/undress, put the arm on my chair's armrest, etc.; This is a spontaneous report from a non-contactable consumer, the patient. A 68-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EN6201) via an unspecified route of administration in the arm left on 15Apr2021 at 10:00 (at the age of 68-year-old) as a single dose for COVID-19 immunisation. The patient had no relevant medical history. The patient did not receive any other medicines within two weeks prior to the COVID-19 vaccine. The patient had no known allergies to medications, food or other products. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the left arm on 17Mar2021 at 10:00 as a single dose for COVID-19 immunisation. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On an15Apr2021, the patient's left arm was so painful for almost 48 hours after the second dose and could barely move the arm, making it difficult to dress/undress, put the arm on the chair's armrest, etc. Therapeutic measures were not taken as a result of the events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events left arm was so painful for almost 48 hours after the second dose and could barely move the arm, making it difficult to dress/undress, put the arm on the chair's armrest, etc. was recovered on 16Apr2021.  No follow-up attempts are possible. No further information is expected.
This spontaneous report as received from a physician via an unspecified reporter, refers to a patient of unknown age and gender. The patient's concurrent conditions and medical history were not reported. On 27-AUG-2014, the patient was vaccinated with a dose of improperly stored PNEUMOVAX 23 "10 Single dose 0.5mLVls 10SDV" and lot number J011998 with expiration date of 12-FEB-2015 (route of administration was unknown), which was stored at 1.11 Celsius Degrees for 208 hours, 0.55 Celsius Degrees for 200 hours, 0 Celsius Degrees for 152 hours and -0.55 Celsius Degrees for 32 hours. The type of excursion was refrigerator and the vaccine status in excursion. No concomitant therapies nor adverse effect were reported. No product quality complaint was involved. This is one of several cases from the same reporter. Additional information has been requested.